Abstract
Olanzapine, a lipophilic antipsychotic drug, has poor oral bioavailability due to hepatic first-pass metabolism. Solid Lipid Nanoparticles (SLNs) of Olanzapine were developed using lipids (Stearic acid and Glyceryl monostearate), soy lecithin, poloxamer 188 and charge modifier stearyl amine by microemulsion technique. The aim of this research was to find out whether the bioavailability of olanzapine can be improved by administering olanzapine SLN orally to Wistar rats. Area under curve was increased (up to 4-fold) and clearance was decreased when olanzapine entrapped in SLNs with stearylamine were administered orally compared with that of olanzapine suspension. The enhanced relative bioavailability by the SLNs formulation might be attributed to avoidance of first-pass hepatic metabolism by intestinal lymphatic transport, direct uptake of nanoparticles through the GI tract, increased permeability by surfactants, and decreased degradation and clearance. These results indicate that olanzapine can be loaded into solid lipid nanoparticles for improvement of its oral bioavailability.
Keywords: Bioavailability, cationic, microemulsion, olanzapine, oral delivery, solid lipid nanoparticles
Current Nanoscience
Title:Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability
Volume: 9 Issue: 1
Author(s): Sumeet Sood, Natarajan Jawahar, Kunal Jain, Kuppusamy Gowthamarajan and Subramania Nainar Meyyanathan
Affiliation:
Keywords: Bioavailability, cationic, microemulsion, olanzapine, oral delivery, solid lipid nanoparticles
Abstract: Olanzapine, a lipophilic antipsychotic drug, has poor oral bioavailability due to hepatic first-pass metabolism. Solid Lipid Nanoparticles (SLNs) of Olanzapine were developed using lipids (Stearic acid and Glyceryl monostearate), soy lecithin, poloxamer 188 and charge modifier stearyl amine by microemulsion technique. The aim of this research was to find out whether the bioavailability of olanzapine can be improved by administering olanzapine SLN orally to Wistar rats. Area under curve was increased (up to 4-fold) and clearance was decreased when olanzapine entrapped in SLNs with stearylamine were administered orally compared with that of olanzapine suspension. The enhanced relative bioavailability by the SLNs formulation might be attributed to avoidance of first-pass hepatic metabolism by intestinal lymphatic transport, direct uptake of nanoparticles through the GI tract, increased permeability by surfactants, and decreased degradation and clearance. These results indicate that olanzapine can be loaded into solid lipid nanoparticles for improvement of its oral bioavailability.
Export Options
About this article
Cite this article as:
Sood Sumeet, Jawahar Natarajan, Jain Kunal, Gowthamarajan Kuppusamy and Nainar Meyyanathan Subramania, Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability, Current Nanoscience 2013; 9 (1) . https://dx.doi.org/10.2174/1573413711309010007
DOI https://dx.doi.org/10.2174/1573413711309010007 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson’s Disease
Current Genomics Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Neuropeptidomics: Improvements in Mass Spectrometry Imaging Analysis and Recent Advancements
Current Protein & Peptide Science The Effectiveness of Treatments for Cocaine Dependence in Schizophrenic Patients: A Systematic Review
Current Neuropharmacology Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research The Effect of PAOPA, a Novel Allosteric Modulator of Dopamine D2 Receptors, on Signaling Proteins Following Sub-Chronic Administration in Rats
Current Molecular Pharmacology Current Therapeutic Options for Alzheimers Disease
Current Genomics Current Research on Opioid Receptor Function
Current Drug Targets Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia
Current Medicinal Chemistry Peak Treadmill Exercise Echocardiography
Reviews on Recent Clinical Trials The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Current Psychopharmacology <i>Withania somnifera</i> in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems
Current Drug Metabolism Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease
Current Topics in Medicinal Chemistry Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets